世界の動物用抗生物質・抗菌剤市場予測(~2026年):製品別(テトラサイクリン、ペニシリン、スルホンアミド、マクロライド、セファロスポリン、リンコサミド)、送達方法別(プレミックス、経口液剤、注射)、動物別(食品製造、コンパニオン)

◆英語タイトル:Animal Antibiotics and Antimicrobials Market by Product (Tetracycline, Penicillin, Sulfonamide, Macrolide, Cephalosporin, Lincosamide), Mode of Delivery (Premixes, Oral Solution, Injection), Animal (Food producing & Companion) - Global Forecast to 2026
◆商品コード:PH2458
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2021年3月8日
◆ページ数:248
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥564,300見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥758,100見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥929,100見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

マーケッツアンドマーケッツ社は世界の動物用抗生物質・抗菌剤市場規模が2021年47億ドルから2026年56億ドルまで、年平均3.6%成長すると予想しています。本市場調査資料では、動物用抗生物質・抗菌剤の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、産業インサイト、製品別(テトラサイクリン、ペニシリン、サルファ剤、マクロライド、アミノグリコシド)分析、送達方法別(プレミックス、経口液剤、経口粉末、注射、その他)分析、動物種類別(食料生産動物、コンパニオンアニマル)分析、地域別分析、競争状況、競争評価マトリックス・企業情報などを掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・産業インサイト
・世界の動物用抗生物質・抗菌剤市場規模:製品別(テトラサイクリン、ペニシリン、サルファ剤、マクロライド、アミノグリコシド)
・世界の動物用抗生物質・抗菌剤市場規模:送達方法別(プレミックス、経口液剤、経口粉末、注射、その他)
・世界の動物用抗生物質・抗菌剤市場規模:動物種類別(食料生産動物、コンパニオンアニマル)
・世界の動物用抗生物質・抗菌剤市場規模:地域別
・競争状況
・競争評価マトリックス・企業情報
【レポートの概要】

“The global animal antimicrobials and antibiotics market is projected to reach USD 5.6 billion by 2026 from USD 4.7 billion in 2021, at a CAGR of 3.6% from 2021 to 2026.”
Market growth can largely be attributed to the rising demand for animal-derived food products, increasing incidence of zoonotic diseases, and the implementation of regulations to prevent the spread of animal diseases. Rising animal healthcare spending and the growing demand for pet insurance are further expected to drive the growth of this market. The untapped emerging markets such as China, India, and Brazil and growth in the overall companion animal population are also expected to offer significant growth opportunities to market players in the coming years
However, the limited number of new antibiotics, growing resistance to antimicrobials and antibiotics, and increasing good husbandry and hygiene practices are expected to hinder the growth of this market to a certain extent.

“The Tetracyclines segment accounted for the largest market share in 2020.”
Based on products, the global animal antimicrobials and antibiotics market is segmented into tetracyclines, penicillins, sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins, and other antimicrobial and antibiotic products. In 2020, the tetracyclines segment accounted for 48.9% of the global animal antimicrobials and antibiotics market. Tetracyclines exhibit advantages such as the highest potency against pathogenic microorganisms, are well-absorbed, show low toxicity, and are relatively inexpensive compared to other animal antimicrobial and antibiotic products. These advantages contribute to the large share of this product segment. The fluoroquinolones segment is expected to grow at the highest CAGR of 8.0% during the forecast period. Advantages such as higher efficacy at low concentrations, quick penetration through tissues, and the availability of variations in the route of administration result in the higher adoption of fluoroquinolones among end users.

“The Premixes segment accounted for the largest market share in 2020.”
Based on the mode of delivery, the global animal antimicrobials and antibiotics market is segmented into premixes, oral powders, oral solutions, injections, and other modes of delivery. In 2020, the premixes segment accounted for the largest share of 46.3% of the global animal antimicrobials and antibiotics market. The large share of this segment can be attributed to the advantages of premixes, such as simplified mode of administration and lower instability and hygroscopicity of formulations. The injections segment is expected to witness the highest CAGR of 4.9% during the forecast period. Advantages such as immediate delivery of drugs and rapid onset of drug effects are expected to drive growth in this market.

“The food producing animal segment accounted for the largest market share in 2020.”
Based on animal type, the global animal antimicrobials and antibiotics market is categorized into food-producing animals and companion animals. In 2020, the food-producing animals segment accounted for the largest share of around 73.4%. This segment is also expected to register the highest CAGR of 3.9% during the forecast period. The large share of this segment is mainly due to the rising demand for animal-derived food products, increase in animal healthcare expenditure, and greater concerns about zoonotic diseases.

“North America was the largest regional market for animal antibiotics and antimicrobials market in 2020.”
The animal antimicrobials and antibiotics market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of 30.3% of the global animal antimicrobials and antibiotics market. The large share of this region is mainly due to the increase in the region’s animal population, rising demand for animal-derived food products, growth in pet insurance, and rising animal health expenditure compared to other regions.

The Asia Pacific region is projected to grow at the highest CAGR of 5.4% during the forecast period. Factors such as the rapidly increasing animal population and rising demand for animal-derived food products are driving the growth of this market in the APAC.

The break-down of primary participants is as mentioned below:
• By Company Type – Tier 1: 40%, Tier 2: 35%, and Tier 3: 25%
• By Designation – C-level: 25%, Director-level: 55%, and Others: 20%
• By Region – North America: 40%, Europe: 25%, Asia Pacific: 20%, Latin America: 10%, and the Middle East & Africa: 5%

Research Coverage:
The report analyzes the animal antimicrobials and antibiotics market and aims at estimating the market size and future growth potential of various market segments, based on by type of product, mode of delivery, animal type, and region.
The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report:
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:
 Market Penetration: Comprehensive information on the product portfolios of the top players in the animal antimicrobials and antibiotics market. The report analyzes this market by type of product, mode of delivery, animal type and region.
 Market Development: Comprehensive information on the lucrative emerging markets, by type of product, mode of delivery, animal type, and region.
 Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the animal antimicrobials and antibiotics market.
 Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the animal antimicrobials and antibiotics market.

【レポートの目次】

1 INTRODUCTION 32
1.1 OBJECTIVES OF THE STUDY 32
1.2 MARKET DEFINITION 32
1.2.1 INCLUSIONS AND EXCLUSIONS 33
1.2.2 MARKETS COVERED 34
1.2.3 YEARS CONSIDERED FOR THE STUDY 34
1.3 CURRENCY 35
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 35
1.4 LIMITATIONS 35
1.5 STAKEHOLDERS 35
1.6 SUMMARY OF CHANGES 36
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH DATA 37
FIGURE 1 RESEARCH DESIGN 37
2.1.1 SECONDARY DATA 37
2.1.1.1 Key data from secondary sources 38
2.1.2 PRIMARY DATA 39
FIGURE 2 PRIMARY SOURCES 39
2.1.2.1 Key data from primary sources 40
2.1.2.2 Key industry insights 40
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 41
2.2 MARKET SIZE ESTIMATION 41
FIGURE 4 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 42
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION 42
FIGURE 6 COUNTRY-LEVEL ANALYSIS OF THE ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET 43
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 44
FIGURE 8 TOP-DOWN APPROACH 45
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 46
FIGURE 9 MARKET DATA TRIANGULATION METHODOLOGY 46
2.4 MARKET SHARE ANALYSIS 46
2.5 ASSUMPTIONS FOR THE STUDY 47
3 EXECUTIVE SUMMARY 48
FIGURE 10 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT,
2021 VS. 2026 (USD MILLION) 48
FIGURE 11 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY MODE OF DELIVERY, 2021 VS. 2026 (USD MILLION) 49
FIGURE 12 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY ANIMAL TYPE, 2021 VS. 2026 (USD MILLION) 49
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET 50
4 PREMIUM INSIGHTS 51
4.1 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET OVERVIEW 51
FIGURE 14 RISING DEMAND FOR ANIMAL-DERIVED FOOD PRODUCTS AND GROWING INCIDENCE OF ZOONOTIC DISEASES TO DRIVE MARKET GROWTH 51
4.2 ASIA PACIFIC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY AND COUNTRY (2020) 52
FIGURE 15 CHINA ACCOUNTED FOR THE LARGEST SHARE OF THE APAC ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET IN 2020 52
4.3 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
FIGURE 16 CHINA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 53
4.4 REGIONAL MIX: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET (2021−2026) 54
FIGURE 17 NORTH AMERICA WILL CONTINUE TO DOMINATE THE ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET IN 2026 54
4.5 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: DEVELOPED VS. DEVELOPING MARKETS 54
FIGURE 18 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES DURING THE FORECAST PERIOD 54
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 55
TABLE 2 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: IMPACT ANALYSIS 55
5.2.1 DRIVERS 56
5.2.1.1 Rising demand for animal-derived food products 56
TABLE 3 PAST AND PROJECTED TRENDS IN THE CONSUMPTION OF MEAT AND MILK IN DEVELOPED AND DEVELOPING REGIONS 56
FIGURE 19 ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS) 57
FIGURE 20 ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS) 57
FIGURE 21 ASIA WAS THE HIGHEST CONSUMER OF MEAT AND MILK IN THE WORLD IN 2018 57
5.2.1.2 Increasing incidence of zoonotic diseases 58
TABLE 4 ANIMAL DISEASE OUTBREAKS IN ASIA PACIFIC COUNTRIES (2009–2019) 58
5.2.1.3 Increasing investments from private players 59
5.2.1.4 Rising demand for pet insurance and growing animal health expenditure 59
FIGURE 22 NORTH AMERICA: PET HEALTH INSURANCE MARKET,
2014 VS. 2019 (USD MILLION) 60
5.2.2 RESTRAINTS 61
5.2.2.1 Limited number of new antibiotics 61
5.2.2.2 Growing resistance to antimicrobials and antibiotics 61
5.2.2.3 Routine prophylactic use of antibiotics being replaced by good husbandry, probiotics, and hygiene practices 62
5.2.3 OPPORTUNITIES 63
5.2.3.1 Untapped emerging markets 63
5.2.3.2 Growth in the companion animal population 64
TABLE 5 US: COMPANION ANIMAL POPULATION (2010–2025) 64
TABLE 6 UK : COMPANION ANIMAL POPULATION (2010–2025) 64
TABLE 7 INDIA : COMPANION ANIMAL POPULATION IN (2010–2025) 64
TABLE 8 SAUDI ARABIA: COMPANION ANIMAL POPULATION (2010–2025) 65
5.2.4 CHALLENGES 65
5.2.4.1 Stringent approval process for antimicrobials and antibiotics 65
6 INDUSTRY INSIGHTS 66
6.1 INTRODUCTION 66
6.2 COVID-19 IMPACT ANALYSIS 66
6.2.1 IMPACT OF COVID-19 ON THE ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET 67
6.3 INDUSTRY TRENDS 68
FIGURE 23 GROWING CONSOLIDATION IN THE ANIMAL HEALTH INDUSTRY IS A MAJOR TREND IN THE ANIMAL ANTIMICROBIALS & ANTIBIOTICS MARKET 68
6.3.1 GROWING CONSOLIDATION IN THE ANIMAL HEALTH INDUSTRY 68
TABLE 9 SOME MAJOR ACQUISITIONS IN THE ANIMAL HEALTH INDUSTRY
(2017–2019) 69
6.3.2 GROWING FOCUS ON LIMITING THE USE OF ANTIBIOTICS IN LIVESTOCK ANIMALS 69
6.3.3 HIGH GROWTH IN EMERGING MARKETS 69
6.4 REGULATORY ANALYSIS 70
FIGURE 24 DEVELOPMENT AND APPROVAL PROCESS FOR ANIMAL PHARMACEUTICAL PRODUCTS 72
6.5 VALUE CHAIN ANALYSIS 72
FIGURE 25 ANIMAL ANTIMICROBIALS AND ANTIBODY MARKET: VALUE CHAIN ANALYSIS 73
6.6 ECOSYSTEM MARKET MAP 73
TABLE 10 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: ECOSYSTEM MAPPING 73
FIGURE 26 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: ECOSYSTEM MARKET MAP 74
6.7 PORTER’S FIVE FORCES ANALYSIS 75
TABLE 11 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 75
6.7.1 THREAT FROM NEW ENTRANTS 76
6.7.2 THREAT FROM SUBSTITUTES 76
6.7.3 BARGAINING POWER OF SUPPLIERS 77
6.7.4 BARGAINING POWER OF BUYERS 77
6.7.5 INTENSITY OF COMPETITIVE RIVALRY 77
6.8 SUPPLY CHAIN ANALYSIS 77
FIGURE 27 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: SUPPLY CHAIN ANALYSIS 79
6.9 PATENT ANALYSIS 79
TABLE 12 LIST OF ANTIBIOTICS AND THEIR PATENT YEARS 80
6.10 PRICING ANALYSIS 80
7 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT 82
7.1 INTRODUCTION 83
FIGURE 28 SALES OF ANTIMICROBIAL AGENTS, BY ANTIMICROBIAL CLASS, AS A PERCENTAGE OF THE TOTAL SALES FOR FOOD-PRODUCING SPECIES (IN MG/PCU): AGGREGATED BY 31 EUROPEAN COUNTRIES, 2018 83
TABLE 13 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 84
TABLE 14 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 84
7.2 TETRACYCLINES 85
7.2.1 REDUCED COST OF TETRACYCLINES IS A KEY FACTOR DRIVING MARKET GROWTH ACROSS THE GLOBE 85
TABLE 15 TETRACYCLINES OFFERED BY KEY MARKET PLAYERS 85
FIGURE 29 SALES OF TETRACYCLINES FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU) 86
TABLE 16 TETRACYCLINES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 86
7.3 PENICILLINS 87
7.3.1 RISING INCIDENCE OF ZOONOTIC DISEASES IN LIVESTOCK ANIMALS TO DRIVE THE DEMAND FOR PENICILLINS 87
TABLE 17 PENICILLINS OFFERED BY KEY MARKET PLAYERS 87
FIGURE 30 SALES OF PENICILLINS FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU) 88
TABLE 18 PENICILLINS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 88
7.4 SULFONAMIDES 89
7.4.1 REDUCED COST AND MULTIPLE APPLICATIONS IN LIVESTOCK INFECTIONS TO DRIVE THE DEMAND FOR SULFONAMIDES IN RURAL REGIONS 89
TABLE 19 SULFONAMIDES OFFERED BY KEY MARKET PLAYERS 89
FIGURE 31 SALES OF SULFONAMIDES FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU) 90
TABLE 20 SULFONAMIDES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 90
7.5 MACROLIDES 91
7.5.1 INCREASING PRODUCTION OF CATTLE-DERIVED FOOD PRODUCTS TO BOOST THE DEMAND FOR MACROLIDES 91
TABLE 21 MACROLIDES OFFERED BY KEY MARKET PLAYERS 91
FIGURE 32 SALES OF MACROLIDES FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU) 92
TABLE 22 MACROLIDES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 92
7.6 AMINOGLYCOSIDES 93
7.6.1 AMINOGLYCOSIDES ARE COMMONLY USED TO CONTROL LOCAL AND SYSTEMIC INFECTIONS CAUSED BY SUSCEPTIBLE AEROBIC BACTERIA (GENERALLY GRAM-NEGATIVE) 93
TABLE 23 AMINOGLYCOSIDES OFFERED BY KEY MARKET PLAYERS 93
FIGURE 33 SALES OF AMINOGLYCOSIDES FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU) 94
TABLE 24 AMINOGLYCOSIDES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 94
7.7 LINCOSAMIDES 95
7.7.1 LINCOSAMIDES EXHIBIT SERIOUS SIDE EFFECTS—A KEY FACTOR LIMITING MARKET GROWTH 95
TABLE 25 LINCOSAMIDES OFFERED BY KEY MARKET PLAYERS 95
FIGURE 34 SALES OF LINCOSAMIDES FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU) 96
TABLE 26 LINCOSAMIDES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 96
7.8 FLUOROQUINOLONES 97
7.8.1 AVAILABILITY OF VARIATIONS IN THE ROUTE OF ADMINISTRATION RESULTS IN THE HIGHER ADOPTION OF FLUOROQUINOLONES AMONG END USERS 97
TABLE 27 FLUOROQUINOLONES OFFERED BY KEY MARKET PLAYERS 97
FIGURE 35 SALES OF FLUOROQUINOLONES FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU) 98
TABLE 28 FLUOROQUINOLONES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 98
7.9 CEPHALOSPORINS 99
7.9.1 CEPHALOSPORINS ARE ACTIVE AGAINST A WIDE RANGE OF BACTERIA—A KEY FACTOR DRIVING MARKET GROWTH 99
TABLE 29 PROPERTIES OF SEVERAL GENERATIONS OF CEPHALOSPORINS 99
TABLE 30 CEPHALOSPORINS OFFERED BY KEY MARKET PLAYERS 100
FIGURE 36 SALES OF FIRST- AND SECOND-GENERATION CEPHALOSPORINS FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU) 100
FIGURE 37 SALES OF THIRD- AND FOURTH-GENERATION CEPHALOSPORINS FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU) 101
TABLE 31 CEPHALOSPORINS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 101
7.10 OTHER ANTIMICROBIALS AND ANTIBIOTICS 102
FIGURE 38 SALES OF POLYMYXINS FOR FOOD-PRODUCING ANIMALS IN EUROPEAN COUNTRIES, 2017 VS. 2018 (MG/PCU) 102
TABLE 32 OTHER ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 103
8 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY 104
8.1 INTRODUCTION 105
TABLE 33 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION) 105

8.2 PREMIXES 105
8.2.1 ADVANTAGES OF PREMIXES, SUCH AS SIMPLIFIED MODE OF ADMINISTRATION AND LOWER INSTABILITY AND HYGROSCOPICITY,
TO DRIVE MARKET GROWTH 105
TABLE 34 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR PREMIXES,
BY COUNTRY, 2019–2026 (USD MILLION) 106
8.3 ORAL SOLUTIONS 107
8.3.1 ORAL SOLUTIONS PRODUCE SYSTEMIC EFFECTS BUT SHOW A RELATIVELY SLOW ONSET OF ACTION 107
TABLE 35 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR ORAL SOLUTIONS, BY COUNTRY, 2019–2026 (USD MILLION) 107
8.4 ORAL POWDERS 108
8.4.1 PROPERTIES SUCH AS BETTER CHEMICAL STABILITY THAN ORAL SOLUTIONS AND FASTER DISSOLUTION THAN TABLETS AND CAPSULES TO DRIVE THE ADOPTION OF ORAL POWDERS 108
TABLE 36 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR ORAL POWDERS, BY COUNTRY, 2019–2026 (USD MILLION) 108
8.5 INJECTIONS 109
8.5.1 INJECTABLE DRUGS PROVIDE SYSTEMIC EFFECTS AND POSSESS GREATER BIOAVAILABILITY, OFFERING A FASTER ONSET OF ACTION 109
TABLE 37 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR INJECTIONS,
BY COUNTRY, 2019–2026 (USD MILLION) 109
8.6 OTHER MODES OF DELIVERY 110
TABLE 38 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR OTHER MODES OF DELIVERY, BY COUNTRY, 2019–2026 (USD MILLION) 111
9 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL 112
9.1 INTRODUCTION 113
TABLE 39 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION) 113
9.2 FOOD-PRODUCING ANIMALS 113
TABLE 40 GLOBAL POPULATION OF FOOD-PRODUCING ANIMALS,
1970–2030 (MILLION) 114
TABLE 41 PER CAPITA CONSUMPTION OF MEAT IN MAJOR APAC COUNTRIES,
2019 (IN KG) 114
TABLE 42 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 115
TABLE 43 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY COUNTRY, 2019–2026 (USD MILLION) 115
9.2.1 CATTLE 116
9.2.1.1 Increasing beef consumption and milk production to drive growth in this market segment 116
TABLE 44 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR CATTLE, BY COUNTRY, 2019–2026 (USD MILLION) 116
9.2.2 PIGS 117
9.2.2.1 Growing incidence of zoonotic diseases will require better health maintenance of pigs—a key factor driving market growth 117
TABLE 45 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR PIGS, BY COUNTRY,
2019–2026 (USD MILLION) 118
9.2.3 POULTRY 118
9.2.3.1 Growing egg consumption in emerging countries to drive market growth 118
FIGURE 39 LEADING EGG PRODUCING COUNTRIES, 2018 (NUMBER OF EGGS, IN BILLION) 119
TABLE 46 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR POULTRY, BY COUNTRY, 2019–2026 (USD MILLION) 119
9.2.4 SHEEP AND GOATS 120
9.2.4.1 Increasing population of sheep and goats to drive growth in this segment 120
TABLE 47 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR SHEEP AND GOATS,
BY COUNTRY, 2019–2026 (USD MILLION) 120
9.2.5 OTHER FOOD-PRODUCING ANIMALS 121
FIGURE 40 PER CAPITA FISH CONSUMPTION, 2019 VS. 2029 121
TABLE 48 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR OTHER FOOD-PRODUCING ANIMALS, BY COUNTRY, 2019–2026 (USD MILLION) 122
9.3 COMPANION ANIMALS 122
TABLE 49 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS,
BY TYPE, 2019–2026 (USD MILLION) 123
TABLE 50 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS,
BY COUNTRY, 2019–2026 (USD MILLION) 123
9.3.1 DOGS 124
9.3.1.1 Growing adoption of dogs to drive growth in this market segment 124
FIGURE 41 GROWING POPULATION OF PET DOGS IN INDIA (MILLION) 124
FIGURE 42 POPULATION OF PET DOGS GLOBALLY (MILLION) 125
TABLE 51 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR DOGS, BY COUNTRY, 2019–2026 (USD MILLION) 125
9.3.2 CATS 126
9.3.2.1 Growing research on feline health and wellbeing to support the market growth 126
TABLE 52 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR CATS, BY COUNTRY,
2019–2026 (USD MILLION) 127
9.3.3 HORSES 127
9.3.3.1 Declining horse population necessitates the adoption of health products—a key factor driving market growth 127
TABLE 53 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR HORSES, BY COUNTRY, 2019–2026 (USD MILLION) 128
9.3.4 OTHER COMPANION ANIMALS 128
TABLE 54 ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY, 2019–2026 (USD MILLION) 129
10 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY REGION 130
10.1 INTRODUCTION 131
TABLE 55 COMPANION ANIMAL AND FOOD-PRODUCING ANIMAL POPULATION,
BY COUNTRY, 2020 (IN THOUSAND) 131
TABLE 56 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY REGION,
2019–2026 (USD MILLION) 131
10.2 NORTH AMERICA 132
FIGURE 43 EXPECTED GROWTH IN THE NUMBER OF VETERINARIANS IN NORTH AMERICA 133
FIGURE 44 NORTH AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET SNAPSHOT 134
TABLE 57 NORTH AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 135
TABLE 58 NORTH AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 135
TABLE 59 NORTH AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY MODE OF DELIVERY, 2019–2026 (USD MILLION) 135
TABLE 60 NORTH AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY TYPE OF ANIMAL, 2019–2026 (USD MILLION) 136
TABLE 61 NORTH AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 136
TABLE 62 NORTH AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 136
10.2.1 US 137
10.2.1.1 Rising pet expenditure and increasing meat consumption are driving the market in the US 137
FIGURE 45 US: GROWTH IN BEEF CONSUMPTION, 2014–2019 (BILLION POUNDS) 137
FIGURE 46 US: INCREASE IN PET EXPENDITURE, 2010–2019 (USD BILLION) 137
FIGURE 47 DOMESTIC SALES AND DISTRIBUTION OF MEDICALLY IMPORTANT ANTIMICROBIAL DRUGS FOR PRODUCTION AND THERAPEUTIC INDICATIONS IN THE US (THOUSAND KG) 139
TABLE 63 US: PRIVATE CLINICAL PRACTICES, BY ANIMAL TYPE, 2016 VS. 2018 139
TABLE 64 US: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 140
TABLE 65 US: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY MODE OF DELIVERY, 2019–2026 (USD MILLION) 140
TABLE 66 US: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY TYPE OF ANIMAL, 2019–2026 (USD MILLION) 140
TABLE 67 US: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 141
TABLE 68 US: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 141
10.2.2 CANADA 141
10.2.2.1 Growing pet adoption rate to drive the market in Canada 141
TABLE 69 CANADA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 142
TABLE 70 CANADA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY MODE OF DELIVERY, 2019–2026 (USD MILLION) 143
TABLE 71 CANADA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY TYPE OF ANIMAL, 2019–2026 (USD MILLION) 143
TABLE 72 CANADA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 143
TABLE 73 CANADA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 144
10.3 EUROPE 144
TABLE 74 EUROPE: LIVESTOCK POPULATION, BY ANIMAL, 2011–2018 (MILLION HEAD) 145
TABLE 75 EUROPE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 145
TABLE 76 EUROPE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 146
TABLE 77 EUROPE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY MODE OF DELIVERY, 2019–2026 (USD MILLION) 146
TABLE 78 EUROPE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY TYPE OF ANIMAL, 2019–2026 (USD MILLION) 146
TABLE 79 EUROPE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 147
TABLE 80 EUROPE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 147
10.3.1 SPAIN 147
10.3.1.1 Large volume of sales of important antibiotics in this country to drive market growth 147
TABLE 81 SPAIN: LARGE ANIMAL POPULATION, 2001–2019 (MILLION) 148
TABLE 82 SPAIN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 148
TABLE 83 SPAIN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY MODE OF DELIVERY, 2019–2026 (USD MILLION) 149
TABLE 84 SPAIN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY TYPE OF ANIMAL, 2019–2026 (USD MILLION) 149
TABLE 85 SPAIN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 149
TABLE 86 SPAIN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 150
10.3.2 ITALY 150
10.3.2.1 Need to curb zoonotic diseases in livestock will contribute to the demand for animal antimicrobials and antibiotics market in Italy 150
TABLE 87 ITALY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 151
TABLE 88 ITALY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY MODE OF DELIVERY, 2019–2026 (USD MILLION) 151
TABLE 89 ITALY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY TYPE OF ANIMAL, 2019–2026 (USD MILLION) 151
TABLE 90 ITALY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 152
TABLE 91 ITALY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 152
10.3.3 GERMANY 152
10.3.3.1 Increasing number of pets, increasing veterinary visits, and growing healthcare expenditure to boost the growth of the animal antimicrobials and antibiotics market in Germany 152
TABLE 92 GERMANY: COMPANION ANIMAL POPULATION, 2012–2018 (MILLION) 153
FIGURE 48 SALES SURVEILLANCE OF ANTIMICROBIALS FOR VETERINARY USE IN GERMANY (2011 TO 2018) 153
TABLE 93 GERMANY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 154
TABLE 94 GERMANY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY MODE OF DELIVERY, 2019–2026 (USD MILLION) 154
TABLE 95 GERMANY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY TYPE OF ANIMAL, 2019–2026 (USD MILLION) 154
TABLE 96 GERMANY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 155
TABLE 97 GERMANY: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 155
10.3.4 FRANCE 155
10.3.4.1 Presence of major players has ensured the strong share of France in the overall market 155
TABLE 98 FRANCE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 156
TABLE 99 FRANCE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY MODE OF DELIVERY, 2019–2026 (USD MILLION) 157
TABLE 100 FRANCE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY TYPE OF ANIMAL, 2019–2026 (USD MILLION) 157
TABLE 101 FRANCE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 157
TABLE 102 FRANCE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 158
10.3.5 UK 158
10.3.5.1 Increasing pet ownership is expected to drive market growth 158
FIGURE 49 SALES OF ANTIBIOTICS FOR FOOD-PRODUCING ANIMALS IN THE UK FROM 2015 TO 2019 (MG/KG) 159
TABLE 103 UK: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 159
TABLE 104 UK: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY MODE OF DELIVERY, 2019–2026 (USD MILLION) 160
TABLE 105 UK: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY TYPE OF ANIMAL, 2019–2026 (USD MILLION) 160
TABLE 106 UK: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 160
TABLE 107 UK: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 161
10.3.6 REST OF EUROPE 161
TABLE 108 ROE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 162
TABLE 109 ROE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY MODE OF DELIVERY, 2019–2026 (USD MILLION) 162
TABLE 110 ROE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY TYPE OF ANIMAL, 2019–2026 (USD MILLION) 163
TABLE 111 ROE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 163
TABLE 112 ROE: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 163
10.4 ASIA PACIFIC (APAC) 164
TABLE 113 ASIA PACIFIC: FOOD-PRODUCING ANIMAL POPULATION,
2010–2017 (MILLION) 164
FIGURE 50 ASIA PACIFIC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET SNAPSHOT 165
TABLE 114 ASIA PACIFIC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 166
TABLE 115 ASIA PACIFIC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 166
TABLE 116 ASIA PACIFIC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY MODE OF DELIVERY, 2019–2026 (USD MILLION) 166
TABLE 117 ASIA PACIFIC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY TYPE OF ANIMAL, 2019–2026 (USD MILLION) 167
TABLE 118 ASIA PACIFIC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 167
TABLE 119 ASIA PACIFIC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 167
10.4.1 CHINA 168
10.4.1.1 China dominates the APAC animal antimicrobials and antibiotics market 168
TABLE 120 CHINA: FOOD-PRODUCING ANIMAL POPULATION, 2012–2019 (MILLION) 168
TABLE 121 CHINA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 169
TABLE 122 CHINA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY MODE OF DELIVERY, 2019–2026 (USD MILLION) 169
TABLE 123 CHINA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY TYPE OF ANIMAL, 2019–2026 (USD MILLION) 170
TABLE 124 CHINA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 170
TABLE 125 CHINA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 170
10.4.2 JAPAN 171
10.4.2.1 Rising demand for imported breeds is driving pet adoption in the country 171
TABLE 126 PRODUCTION AND CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS
IN JAPAN (2000 VS. 2030) (THOUSAND METRIC TONS) 171
FIGURE 51 VOLUMES OF VETERINARY ANTIMICROBIALS SOLD BY PHARMACEUTICAL COMPANIES IN JAPAN, 2001–2017 (IN TONS OF ACTIVE INGREDIENT) 172
FIGURE 52 AMOUNT OF ANTIMICROBIAL FEED ADDITIVES MANUFACTURED IN JAPAN, 2003–2017 (IN TONS OF ACTIVE INGREDIENT) 173
TABLE 127 JAPAN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 173
TABLE 128 JAPAN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY MODE OF DELIVERY, 2019–2026 (USD MILLION) 174
TABLE 129 JAPAN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY TYPE OF ANIMAL, 2019–2026 (USD MILLION) 174
TABLE 130 JAPAN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 174
TABLE 131 JAPAN: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 175
10.4.3 INDIA 175
10.4.3.1 Rising food-producing animal population and growing awareness about animal health will contribute to market growth during the forecast period 175
TABLE 132 PRODUCTION AND CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS IN INDIA (2000 VS. 2030) (THOUSAND METRIC TONS) 176
TABLE 133 INDIA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 176
TABLE 134 INDIA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY MODE OF DELIVERY, 2019–2026 (USD MILLION) 177
TABLE 135 INDIA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY TYPE OF ANIMAL, 2019–2026 (USD MILLION) 177
TABLE 136 INDIA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 177
TABLE 137 INDIA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 178
10.4.4 REST OF ASIA PACIFIC (REST OF APAC) 178
TABLE 138 REGULATORY SCENARIO FOR ANTIBIOTICS IN THE ROAPAC, BY COUNTRY 178
TABLE 139 REST OF APAC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 179
TABLE 140 REST OF APAC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY MODE OF DELIVERY, 2019–2026 (USD MILLION) 179
TABLE 141 REST OF APAC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY TYPE OF ANIMAL, 2019–2026 (USD MILLION) 179
TABLE 142 REST OF APAC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 180
TABLE 143 REST OF APAC: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 180
10.5 LATIN AMERICA 180
TABLE 144 LATIN AMERICA: FOOD-PRODUCING ANIMALS POPULATION, BY COUNTRY (2010–2014) (MILLION) 181
TABLE 145 LATIN AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 181
TABLE 146 LATIN AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY MODE OF DELIVERY, 2019–2026 (USD MILLION) 182
TABLE 147 LATIN AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET,
BY TYPE OF ANIMAL, 2019–2026 (USD MILLION) 182
TABLE 148 LATIN AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 182
TABLE 149 LATIN AMERICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 183
10.6 MIDDLE EAST & AFRICA 183
TABLE 150 AFRICA: NUMBER OF VETERINARIANS, 2010 VS. 2014 VS. 2016 184
TABLE 151 MIDDLE EAST & AFRICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 184
TABLE 152 MIDDLE EAST & AFRICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY MODE OF DELIVERY, 2019–2026 (USD MILLION) 185
TABLE 153 MIDDLE EAST & AFRICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, BY TYPE OF ANIMAL, 2019–2026 (USD MILLION) 185
TABLE 154 MIDDLE EAST & AFRICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR FOOD-PRODUCING ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 185
TABLE 155 MIDDLE EAST & AFRICA: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2019–2026 (USD MILLION) 186
11 COMPETITIVE LANDSCAPE 187
11.1 INTRODUCTION 187
FIGURE 53 KEY DEVELOPMENTS OF MAJOR PLAYERS BETWEEN 2017 AND JAN 2021 188
11.2 MARKET EVALUATION FRAMEWORK 189
FIGURE 54 MARKET EVALUATION FRAMEWORK: ACQUISITIONS—THE MOST WIDELY ADOPTED STRATEGY 189
11.3 PRODUCT PORTFOLIO MATRIX 190
TABLE 156 PLAYERS IN THE ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: PRODUCT PORTFOLIO ANALYSIS 190
11.4 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: GEOGRAPHICAL ASSESSMENT 191
FIGURE 55 GEOGRAPHIC ASSESSMENT OF KEY PLAYERS IN THE ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET (2019) 191
11.5 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: R&D EXPENDITURE 192
FIGURE 56 R&D EXPENDITURE OF KEY PLAYERS IN THE ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET (2019) 192
11.6 REVENUE ANALYSIS: TOP 5 PLAYERS 192
FIGURE 57 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: REVENUE ANALYSIS (2019) 193
11.7 VENDOR DIVE 193
11.7.1 STARS 193
11.7.2 EMERGING LEADERS 194
11.7.3 PERVASIVE PLAYERS 194
11.7.4 EMERGING COMPANIES 194
FIGURE 58 COMPETITIVE LEADERSHIP MAPPING: ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET, 2020 195
11.8 MARKET SHARE ANALYSIS 196
TABLE 157 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: DEGREE OF COMPETITION 196
FIGURE 59 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2020 196
11.9 COMPETITIVE SITUATION AND TRENDS 197
11.9.1 PRODUCT LAUNCHES & APPROVALS 197
TABLE 158 PRODUCT LAUNCHES & APPROVALS 197
11.9.2 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS 198
TABLE 159 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS 198
11.9.3 MERGERS, ACQUISITIONS, AND DIVESTITURES 198
TABLE 160 MERGERS, ACQUISITIONS, AND DIVESTITURES 198
11.9.4 EXPANSIONS 199
TABLE 161 EXPANSIONS 199
11.10 SME MATRIX 199
11.10.1 COMPETITIVE LEADERSHIP MAPPING (SMES) 199
11.10.1.1 Progressive companies 199
11.10.1.2 Starting blocks 199
11.10.1.3 Responsive companies 200
11.10.1.4 Dynamic companies 200
FIGURE 60 ANIMAL ANTIMICROBIALS AND ANTIBIOTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR SME, 2020 200
12 COMPETITIVE EVALUATION MATRIX AND COMPANY PROFILES 201
12.1 KEY PLAYERS 201
(Business overview, Products offered, Recent developments, MNM view)*
12.1.1 ZOETIS, INC. 201
TABLE 162 ZOETIS, INC.: BUSINESS OVERVIEW 201
FIGURE 61 ZOETIS: COMPANY SNAPSHOT (2019) 202
12.1.2 MERCK & CO., INC. 206
TABLE 163 MERCK AND CO., INC: BUSINESS OVERVIEW 206
FIGURE 62 MERCK & CO., INC.: COMPANY SNAPSHOT (2019) 207
12.1.3 BOEHRINGER INGELHEIM GMBH 210
TABLE 164 BOEHRINGER INGELHEIM GMBH: BUSINESS OVERVIEW 210
FIGURE 63 BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT (2019) 210
12.1.4 ELANCO ANIMAL HEALTH 214
TABLE 165 ELANCO ANIMAL HEALTH: BUSINESS OVERVIEW 214
FIGURE 64 ELANCO ANIMAL HEALTH: COMPANY SNAPSHOT (2019) 215
12.1.5 CEVA SANTÉ ANIMALE 219
TABLE 166 CEVA SANTÉ ANIMALE: BUSINESS OVERVIEW 219
12.1.6 VIRBAC 222
TABLE 167 VIRBAC: BUSINESS OVERVIEW 222
FIGURE 65 VIRBAC: COMPANY SNAPSHOT (2019) 222
12.1.7 VETOQUINOL SA. 225
TABLE 168 VETOQUINOL S.A.: BUSINESS OVERVIEW 225
FIGURE 66 VETOQUINOL SA: COMPANY SNAPSHOT (2019) 225
12.1.8 DECHRA PHARMACEUTICALS PLC 228
TABLE 169 DECHRA PHARMACEUTICALS PLC: BUSINESS OVERVIEW 228
FIGURE 67 DECHRA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2019) 229
12.1.9 PHIBRO ANIMAL HEALTH 232
TABLE 170 PHIBRO ANIMAL HEALTH: BUSINESS OVERVIEW 232
FIGURE 68 PHIBRO ANIMAL HEALTH: COMPANY SNAPSHOT (2019) 232
12.1.10 KYORITSU SEIYAKU 234
TABLE 171 KYORITSU SEIYAKU: BUSINESS OVERVIEW 234
12.1.11 ZYDUS ANIMAL HEALTH 236
TABLE 172 ZYDUS ANIMAL HEALTH: BUSINESS OVERVIEW 236
FIGURE 69 ZYDUS: COMPANY SNAPSHOT (2019) 236
12.1.12 TIANJIN RINGPU 239
TABLE 173 TIANJIN RINGPU: BUSINESS OVERVIEW 239
12.1.13 HIPRA 240
TABLE 174 HIPRA: BUSINESS OVERVIEW 240
12.1.14 CHINA ANIMAL HUSBANDRY 241
TABLE 175 CHINA ANIMAL HUSBANDRY: BUSINESS OVERVIEW 241
12.1.15 INOVET 242
TABLE 176 INOVET: BUSINESS OVERVIEW 242
*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.
12.2 OTHER EMERGING COMPANIES 245
12.2.1 ENDOVAC ANIMAL HEALTH 245
12.2.2 ECO ANIMAL HEALTH GROUP PLC 245
12.2.3 INDIAN IMMUNOLOGICALS LTD. 245
12.2.4 ASHISH LIFE SCIENCE (ALS) 246
12.2.5 LUTIM PHARMA 246
13 APPENDIX 247
13.1 DISCUSSION GUIDE 247
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 251
13.3 AVAILABLE CUSTOMIZATIONS 253
13.4 RELATED REPORTS 254
13.5 AUTHOR DETAILS 255



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の動物用抗生物質・抗菌剤市場予測(~2026年):製品別(テトラサイクリン、ペニシリン、スルホンアミド、マクロライド、セファロスポリン、リンコサミド)、送達方法別(プレミックス、経口液剤、注射)、動物別(食品製造、コンパニオン)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆